Akari Therap | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD -4.6 M.

Research and Development Expenses

Research and development expenses for Akari Therapeutics, Plc were $2.1 million for the second quarter of 2026, an increase from $0.7 million for the second quarter of 2025. This rise primarily reflects expanded development and manufacturing activities supporting the advancement of AKTX-101.

General and Administrative Expenses

General and administrative expenses for the second quarter of 2026 were $2.5 million, which was comparable to the $2.5 million reported for the same period in 2025.

Net Loss

The net loss for the second quarter of 2026 was - $4.8 million, compared with - $1.9 million for the second quarter of 2025.

Cash Position

Akari Therapeutics, Plc’s cash totaled $7.7 million as of June 30, 2026, an increase from $5.2 million as of December 31, 2025.

Financing Activities

During the quarter, Akari Therapeutics, Plc strengthened its balance sheet through financing activities, securing $5.5 million in gross proceeds from a private placement and $3.1 million in gross proceeds from warrant exercises, totaling approximately $8.6 million in gross proceeds. This resulted in approximately $8.0 million of net proceeds to the company.

Operational Progress and Strategic Collaborations

Akari Therapeutics, Plc continued advancing AKTX-101 through IND-enabling activities, progressing manufacturing and development work. The company expanded its strategic position in novel antibody-drug conjugate (ADC) payloads through a research collaboration with Whitehawk Therapeutics to evaluate Akari’s proprietary PH1 spliceosome modulating payload platform. Additionally, Akari Therapeutics, Plc presented breakthrough preclinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and expanded its intellectual property portfolio through newly issued international patents for its proprietary PH1 spliceosome modulating payload technology.

Outlook

Akari Therapeutics, Plc remains focused on initiating AKTX-101 for clinical development in mid-2027. The company is executing IND-enabling work required to support its planned Phase 1 trial in mid-2027. The goal is to start its First-In-Human trial by mid-2027.